Nachrichten zur TG Therapeutics Inc. Aktie

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of…

G1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcript

…

TG Therapeutics, Inc. (TGTX) Q4 2023 Earnings Call Transcript

…

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update

Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET Conference call to be held Wednesday, February…

Precision BioSciences secures $17.5 million from TG Therapeutics By Investing.com

Precision BioSciences secures $17.5 million from TG Therapeutics…

TG Therapeutics: Inferred Expectations Point To Undervalued Shares

…

TG Therapeutics: Indications Of Slowing Market Growth For Briumvi

…

TG Therapeutics prelim results sees FY23 BRIUMVI U.S. revenue $89M; initiates FY24 outlook

…

TG Therapeutics agrees to purchase a global license to a Car T cell therapy program for autoimmune diseases

…

TG Therapeutics spikes; to present at J. P. Morgan conference

…

TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Presentation scheduled for Tuesday, January 9, 2024, at 4:30 PM PT Presentation scheduled for Tuesday, January 9, 2024, at 4:30…

TG Therapeutics: The Revenue Beat Isnt What It Looks Like

…

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology…

TG Therapeutics: Trying To Fill The Gap Back To $20

…

TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Fireside chat scheduled for Wednesday, November 29, 2023, at 2:10 PM ET Fireside chat scheduled for Wednesday, November 29, 2023,…

XFRA ISIN CHANGE

Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen US9183851057 vTv Therapeutics Inc. 20.11.2023 US9183852048 vTv Therapeutics…

TG Therapeutics, Inc. (TGTX) Q3 2023 Earnings Call Transcript

…

TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference

Fireside chat scheduled for Monday, November 6, 2023, at 3:10 PM ET Fireside chat scheduled for Monday, November 6, 2023,…

TG Therapeutics: Q3 Earnings Spike Hard To Explain Given Rivals Numbers

…

G1 Therapeutics, Inc. (GTHX) Q3 2023 Earnings Call Transcript

…

TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update

Conference call to be held Wednesday, November 1, 2023, at 8:30 AM ET Conference call to be held Wednesday, November…

TG Therapeutics: Things Are Stacking Up Against Briumvi

…

TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the presentation of data…

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations,…

TG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

Fireside chat scheduled for Tuesday, September 26, 2023, at 12:25 PM ET Fireside chat scheduled for Tuesday, September 26, 2023,…

TG Therapeutics falls as Cantor tracks latest Briumvi sales data

…

Insiderhandel: CEO and President kauft Aktien von TG Therapeutics im Wert von 1.013.000$

Weiss, Michael S. - Vorstand - Tag der Transaktion: 2023-08-11...…

TG Therapeutics spikes as CEO buys $1M shares

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 10-Q TG THERAPEUTICS, INC. For: Jun 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why TG Therapeutics Stock Is Crashing Today

The drugmaker delivered a couple of surprises in Q2....…

TG Therapeutics Shares Tumble 46% After Profit, Revenue Miss Estimates

TG Therapeutics Shares Tumble 46% After Profit, Revenue Miss Estimates...…

Adamis, ABVC top healthcare gainers; TG Therapeutics, Invo among losers

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

TG Therapeutics (TGTX) Reports Q2 Loss, Tops Revenue Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -30.77% and 15.75%, respectively, for the quarter ended June 2023. Do…

TG Therapeutics plunges after Q2 miss

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

Second quarter 2023 BRIUMVI® net sales of $16 million in the United States, representing 100% quarter over quarter growth; total…

TG Therapeutics falls as Roche succeeds in Phase 3 trial for multiple sclerosis therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

TG Therapeutics rises as Cantor sees strong Briumvi sales again

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Insiderhandel: Aufsichtsrat verkauft Aktien von TG Therapeutics im Wert von 814.538$

Lonial, Sagar - Aufsichtsrat - Tag der Transaktion: 2023-06-23...…

TG Therapeutics started at buy at Jefferies on MS asset Briumvi

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

TG Therapeutics to Participate in the 2023 Jefferies Healthcare Conference

Fireside chat scheduled for Wednesday, June 7, 2023, at 11:30 AM ET Fireside chat scheduled for Wednesday, June 7, 2023,…

TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting

NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from…

TG Therapeutics granted EU nod for multiple sclerosis therapy Briumvi

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

TG Therapeutics Announces European Commission Approval for BRIUMVI® (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults

NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the European Commission (EC)…

TG Therapeutics Announces Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting

NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the details of an upcoming…

Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today

These three biotech stocks were on the volatile side today....…

TG Therapeutics Stock Jumps as 1Q Loss Narrows, Profit Surges

TG Therapeutics Stock Jumps as 1Q Loss Narrows, Profit Surges...…

TG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of 22.22% and 105.94%, respectively, for the quarter ended March 2023. Do…

Form 8-K TG THERAPEUTICS, INC. For: May 01

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

TG Therapeutics GAAP EPS of -$0.28 beats by $0.07, revenue of $7.8M beats by $4.42M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

First quarter 2023 BRIUMVI net sales of $7.8 million...…